Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV

Cindy Houwen; Nico van Lisdonk; Jelle Bolier; Michelle van Eekeren; Mandy van Gaalen; Aline van Herk; Zaïd Paula; Natasja Peters; Martijn den Reijer; Kelly Mertens; Khoa T.D. Thai

doi:10.1016/j.diagmicrobio.2023.115970

Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV

Cindy Houwen, Nico van Lisdonk, Jelle Bolier, Michelle van Eekeren, Mandy van Gaalen, Aline van Herk, Zaïd Paula, Natasja Peters, Martijn den Reijer, Kelly Mertens, Khoa T.D. Thai^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

Abstract

We evaluated the diagnostic performance of 4 commercially NAAT for detecting SARS-CoV-2 RNA, Influenza type A/B virus and RSV. Included tests were the Allplex™ SARS-CoV-2 fast PCR Assay (RNA extraction-free), Allplex™ RV Master Assay, Allplex™ SARS-CoV-2 fast MDx Assay (LAMP) and Aptima™ SARS-CoV-2/Flu Assay (RT-TMA). The assays’ performance characteristics were determined using nasopharyngeal swabs from 270 patients with suspected SARS-CoV-2 infection. A total of 215 SARS-CoV-2 positive, 55 negative nasopharyngeal swabs and 19 bacteria strains were included. The sensitivities and specificities for detecting SARS-CoV-2, Influenza type A virus and RSV ranged between 81.8% and 100% with extremely good agreements (κ ≥ 86.8 %). The Aptima™ SARS-CoV-2/Flu Assay introduced a new result parameter, that is, TTime. Here, we showed that TTime may be used as a surrogate for Ct-value. We concluded that all assays assessed in this study can be used for routine detection of SARS-CoV-2, Influenza type A virus and RSV.

Original language	English
Article number	115970
Journal	Diagnostic Microbiology and Infectious Disease
Volume	106
Issue number	4
DOIs	https://doi.org/10.1016/j.diagmicrobio.2023.115970
Publication status	Published - Aug 2023

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.diagmicrobio.2023.115970

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124101/pdf/main.pdf

Cite this

Houwen, C., van Lisdonk, N., Bolier, J., van Eekeren, M., van Gaalen, M., van Herk, A., Paula, Z., Peters, N., den Reijer, M., Mertens, K., & Thai, K. T. D. (2023). Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV. Diagnostic Microbiology and Infectious Disease, 106(4), Article 115970. https://doi.org/10.1016/j.diagmicrobio.2023.115970

@article{343300917ca440f2b3fca4b59bb21d1d,

title = "Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV",

abstract = "We evaluated the diagnostic performance of 4 commercially NAAT for detecting SARS-CoV-2 RNA, Influenza type A/B virus and RSV. Included tests were the Allplex{\texttrademark} SARS-CoV-2 fast PCR Assay (RNA extraction-free), Allplex{\texttrademark} RV Master Assay, Allplex{\texttrademark} SARS-CoV-2 fast MDx Assay (LAMP) and Aptima{\texttrademark} SARS-CoV-2/Flu Assay (RT-TMA). The assays{\textquoteright} performance characteristics were determined using nasopharyngeal swabs from 270 patients with suspected SARS-CoV-2 infection. A total of 215 SARS-CoV-2 positive, 55 negative nasopharyngeal swabs and 19 bacteria strains were included. The sensitivities and specificities for detecting SARS-CoV-2, Influenza type A virus and RSV ranged between 81.8% and 100% with extremely good agreements (κ ≥ 86.8 %). The Aptima{\texttrademark} SARS-CoV-2/Flu Assay introduced a new result parameter, that is, TTime. Here, we showed that TTime may be used as a surrogate for Ct-value. We concluded that all assays assessed in this study can be used for routine detection of SARS-CoV-2, Influenza type A virus and RSV.",

author = "Cindy Houwen and {van Lisdonk}, Nico and Jelle Bolier and {van Eekeren}, Michelle and {van Gaalen}, Mandy and {van Herk}, Aline and Za{\"i}d Paula and Natasja Peters and {den Reijer}, Martijn and Kelly Mertens and Thai, {Khoa T.D.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = aug,

doi = "10.1016/j.diagmicrobio.2023.115970",

language = "English",

volume = "106",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "4",

}

Houwen, C, van Lisdonk, N, Bolier, J, van Eekeren, M, van Gaalen, M, van Herk, A, Paula, Z, Peters, N, den Reijer, M, Mertens, K & Thai, KTD 2023, 'Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV', Diagnostic Microbiology and Infectious Disease, vol. 106, no. 4, 115970. https://doi.org/10.1016/j.diagmicrobio.2023.115970

TY - JOUR

T1 - Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV

AU - Houwen, Cindy

AU - van Lisdonk, Nico

AU - Bolier, Jelle

AU - van Eekeren, Michelle

AU - van Gaalen, Mandy

AU - van Herk, Aline

AU - Paula, Zaïd

AU - Peters, Natasja

AU - den Reijer, Martijn

AU - Mertens, Kelly

AU - Thai, Khoa T.D.

PY - 2023/8

Y1 - 2023/8

N2 - We evaluated the diagnostic performance of 4 commercially NAAT for detecting SARS-CoV-2 RNA, Influenza type A/B virus and RSV. Included tests were the Allplex™ SARS-CoV-2 fast PCR Assay (RNA extraction-free), Allplex™ RV Master Assay, Allplex™ SARS-CoV-2 fast MDx Assay (LAMP) and Aptima™ SARS-CoV-2/Flu Assay (RT-TMA). The assays’ performance characteristics were determined using nasopharyngeal swabs from 270 patients with suspected SARS-CoV-2 infection. A total of 215 SARS-CoV-2 positive, 55 negative nasopharyngeal swabs and 19 bacteria strains were included. The sensitivities and specificities for detecting SARS-CoV-2, Influenza type A virus and RSV ranged between 81.8% and 100% with extremely good agreements (κ ≥ 86.8 %). The Aptima™ SARS-CoV-2/Flu Assay introduced a new result parameter, that is, TTime. Here, we showed that TTime may be used as a surrogate for Ct-value. We concluded that all assays assessed in this study can be used for routine detection of SARS-CoV-2, Influenza type A virus and RSV.

AB - We evaluated the diagnostic performance of 4 commercially NAAT for detecting SARS-CoV-2 RNA, Influenza type A/B virus and RSV. Included tests were the Allplex™ SARS-CoV-2 fast PCR Assay (RNA extraction-free), Allplex™ RV Master Assay, Allplex™ SARS-CoV-2 fast MDx Assay (LAMP) and Aptima™ SARS-CoV-2/Flu Assay (RT-TMA). The assays’ performance characteristics were determined using nasopharyngeal swabs from 270 patients with suspected SARS-CoV-2 infection. A total of 215 SARS-CoV-2 positive, 55 negative nasopharyngeal swabs and 19 bacteria strains were included. The sensitivities and specificities for detecting SARS-CoV-2, Influenza type A virus and RSV ranged between 81.8% and 100% with extremely good agreements (κ ≥ 86.8 %). The Aptima™ SARS-CoV-2/Flu Assay introduced a new result parameter, that is, TTime. Here, we showed that TTime may be used as a surrogate for Ct-value. We concluded that all assays assessed in this study can be used for routine detection of SARS-CoV-2, Influenza type A virus and RSV.

UR - http://www.scopus.com/inward/record.url?scp=85161275838&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2023.115970

DO - 10.1016/j.diagmicrobio.2023.115970

M3 - Article

C2 - 37290260

AN - SCOPUS:85161275838

SN - 0732-8893

VL - 106

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 4

M1 - 115970

ER -

Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this